A Phase I Trial of LY3143921 Hydrate in Solid Tumours

Exclusion criteria

• . Systemic anti-cancer therapy (with the exception of life-long hormone suppression such as luteinising hormone-releasing hormone agents in prostate cancer) or another investigational agent during the previous 4 weeks (6 weeks for nitrosureas, Mitomycin-C) is not permitted. Previous use of radiotherapy is permitted except where there has been a large volume of bone marrow irradiated or where the irradiated lesion is the only one suitable for RECIST measurability.
• . Ongoing toxic manifestations of previous treatments (Grade 2 or greater according to NCI-CTCAE version 4.02) with the exception of alopecia or certain Grade 2 toxicities, which in the opinion of the investigator and Sponsor should not exclude the patient - these should be discussed on a case by case basis.
• . Symptomatic brain metastases or spinal cord compression.
• . Significant baseline hypotension or symptomatic hypotension at any level of BP (\<90 mmgHg systolic or \<50 mmHg diastolic).
• . Uncontrolled hypertension (\>160 mmHg/100 mmHg).
• . Patients with a known left ventricular ejection fraction \<50%. An echocardiogram must be performed in all patients.
• . Women of child-bearing potential (or who are already pregnant or lactating). However, those patients who meet the following points are considered eligible:
• . Male patients with partners of child-bearing potential. However, those patients who meet the following points are considered eligible: